OPK
OPK clinical trials: OPKO HEALTH, INC.
Every trial on ClinicalTrials.gov where OPKO HEALTH, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 55
- Trials linked
- 53
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
OPK on the catalyst calendar · OPK registry changes
- Primary completion Jan 2028Sponsor estimatePhase 1/Phase 2NCT07249905Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaModeX Therapeutics, An OPKO Health Company · LymphomaRecruitingOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 1/Phase 2NCT06239194Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsModeX Therapeutics, An OPKO Health Company · Biliary Tract CancerRecruitingOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 1NCT07445971A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.ModeX Therapeutics, An OPKO Health Company · COVID -19RecruitingOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 1/Phase 2NCT07512427Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH ParticipantsOPKO Health, Inc. · MASHRecruitingOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2027Sponsor estimatePhase 2NCT07494045Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric ParticipantsOPKO Health, Inc. · CKD Stage 3RecruitingOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 24, 2021ActualPhase 2NCT03602261Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDIOPKO Health, Inc. · Secondary Hyperparathyroidism Due to Renal CausesTerminatedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2031Sponsor estimatePhase 1/Phase 2NCT07110584Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced TumorsModeX Therapeutics, An OPKO Health Company · Advanced TumorsRecruitingOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 19, 2024ActualPhase 3NCT05543928Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary HyperparathyroidismOPKO Health, Inc. · Chronic Kidney Disease stage3TerminatedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2019ActualPhase 3NCT02968004Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenOPKO Health, Inc. · Pediatric Growth Hormone DeficiencyCompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2023ActualPhase 2NCT02500316Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenOPKO Health, Inc. · Growth Hormone Deficiency (GHD)CompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 8, 2021ActualPhase 2NCT04551911Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19OPKO Health, Inc. · COVID-19CompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 24, 2020ActualPhase 4NCT03588884Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose...OPKO Health, Inc. · Secondary Hyperparathyroidism Due to Renal CausesCompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2016ActualPhase 3NCT01909479A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone DeficiencyOPKO Health, Inc. · Adult Growth Hormone DeficiencyTerminatedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 18, 2019ActualPhase 2NCT03297398Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)OPKO Health, Inc. · Benign Prostatic HyperplasiaTerminatedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 6, 2020ActualPhase 3NCT03874013Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone DeficiencyOPKO Health, Inc. · Growth Hormone DeficiencyCompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualPhase 1NCT02188303A Study of LY2944876 in Healthy Japanese and Non-Japanese ParticipantsOPKO Health, Inc. · Healthy VolunteersTerminatedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2015ActualPhase 2NCT02119819A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 DiabetesOPKO Health, Inc. · Diabetes Mellitus, Type 2CompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 8, 2019ActualPhase 2NCT03406377Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes SubjectsOPKO Health, Inc. · Type 2 Diabetes MellitusCompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2018ActualPhase 1NCT02418793A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or BOPKO Health, Inc. · Hemophilia ACompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2020ActualNo phase registeredNCT04063644Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye PatientsOPKO Health, Inc. · Dry Eye SyndromesCompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2020ActualNo phase registeredNCT03762408Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis.OPKO Health, Inc. · Osteoarthritis, KneeCompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 19, 2019ActualPhase 1NCT03810664A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product PresentationsOPKO Health, Inc. · Healthy Male VolunteersCompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2015ActualPhase 2NCT01592500Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenOPKO Health, Inc. · Pediatric Growth Hormone DeficiencyCompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2014ActualPhase 2NCT01791725A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without DementiaOPKO Health, Inc. · Down SyndromeCompletedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2015ActualPhase 2NCT01766336A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's DiseaseOPKO Health, Inc. · Alzheimer's DiseaseTerminatedOPKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 30 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner